1. Is a Korean , dyslipidemic outpatient
2. Is eligible for LDL-lowering drug therapy at screening and baseline as determined by
the following LDL-cholesterol (LDL-C) cut-off points defined by NCEP ATP Ⅲ: 2. 1 LDL-C
≥ 190 mg/dL for subjects with 0 or 1 CHD risk factor 2. 2 LDL-C ≥ 160 mg/dL for
subjects with 2 or more CHD risk factors and 10 year risk
mg/dL for subjects with 2 or more CHD risk factors and 10 year risk 10-20 % 2. 4 LDL-C
≥ 100 mg/dL for subjects with documented CHD or CHD risk equivalents (10-year risk >
20 %)
3. Has LDL-C ≤ 220mg/dL at baseline 4. Has triglyceride level ≤ 600mg/dL at baseline
1. Is pregnant or lactating
2. Has present myopathy or history of myopathy or has personal or familial history of
hereditary muscular disorders or any history of rhabdomyolysis
3. Has history of intolerance or hypersensitivity to atorvastatin or other statins
4. Uncontrolled hypertension (i.e. moderate hypertension, sitting systolic BP ? 160mmHg
and/or diastolic BP ? 100mmHg)
5. Has HbAlc > 10%
6. Has any severe disease of has had any major problem or surgical procedure within the 3
months prior to screening that is likely to jeopardize the planned termination of the
study. (e.g., any carcinoma, coronary angioplasty, coronary artery bypass graft,
cardiac infarct, severe or unstable angina pectoris)